Entering text into the input field will update the search result below

CRISPR gene editing shows promise in diabetes

Sep. 17, 2019 7:35 AM ETCRISPR Therapeutics AG (CRSP) StockCRSPBy: Douglas W. House, SA News Editor9 Comments
  • CRISPR Therapeutics (NASDAQ:CRSP) and collaboration partner Viacyte announce encouraging data on the use of CRISPR/Cas9 to edit a pluripotent stem cell line called CyT49 that is being used to generate islet progenitor cells for type 1 diabetes (T1D) clinical trials. The data were presented at the Annual Meeting of the European Association for the Study of Diabetes in Barcelona.
  • The results showed that CyT49 can be successfully edited with CRISPR. The ultimate goal is the creation of an immune system-evading cell replacement therapy for T1D, an autoimmune disorder in which the body's immune system destroys certain cells in the pancreas that make insulin.
  • The companies are currently evaluating a preclinical-stage candidate.

Recommended For You

About CRSP Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CRSP--
CRISPR Therapeutics AG